Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
US giant AutoNation eyes driving seat at Inchcape UK
A takeover of Inchcape's UK dealerships would come months after AutoNation withdrew from a bidding war for rival British company Pendragon, Sky News learns.
150,000 share trade just gone through at 40.5p
Trademark not copyright
Dryrobe has agreed to “cease use of the [stylised Dryrobe sign] or any marks which contain the element 'dry' depicted using any member of the Helvetica family of fonts both on product and across all point of sale and digital materials”, as well as not to order more stock featuring the sign.
A spokesman for Superdry said: "Superdry is pleased to have reached a settlement with Dryrobe in its High Court claim for damages concerning the breach of a previous agreement, whereby Dryrobe would not order more stock featuring a logo which infringed Superdry’s brand.
"The terms of the settlement are confidential. Superdry will always take all necessary steps to protect its brand and intellectual property."
In January, Superdry filed a claim against Manchester City Football Club over an alleged trademark infringement, requesting an “injunction to restrain” it from using the words "Super 'Dry' Asahi 0.0%" on its men’s and women’s team training kits.
Superdry settles trademark dispute
High street fashion brand Superdry has reached a settlement with outdoorwear brand Dryrobe in a trademark dispute filed on 3 August 2023.
BY SABINA WESTON
26 FEBRUARY 2024
Up 18 per cent
Just managed to invest the other 10k in 2 x 5k
I have managed to buy £20,000 this morning in 2 x £10,000. I have another £10,000 which I am trying to get a quote for
Tips as a buyout/takeover
HVIVO (AIM: HVO)
At a challenging time for many larger contract research organizations, London-based hVIVO has grown by specializing in human-challenge clinical trials of infectious and respiratory disease vaccines and antivirals. hVIVO won six major contracts in 2023 totaling £41.9 million (about $53 million) and kicked off 2024 with a £6.3 million (about $8 million) agreement to conduct a Phase IIa human challenge trial of a human rhinovirus candidate being developed by an undisclosed biotechnology client. HVO stock soared 162% during 2023, making the company a potentially attractive target: “hVIVO’s valuation is, in our mind, undemanding, for the highly visible near-term growth we expect and consistent delivery of targets by management,” Cavendish Global observed.
From Genetic Engineering
&Biotechnology News, yesterday
I said more than 1 rns this week
Clinical trial specialist Hvivo will start paying an annual dividend from this year as it cashes in on rising demand for its services.
The group, which recruits healthy adult volunteers and infects them with a medical-grade version of a virus to test the effectiveness of drugs and vaccines being developed by biotech and pharmaceutical companies, reported that revenues increased 15.5 per cent to £56million in 2023.
In a further dose of good news, Hvivo has already secured 90 per cent of its revenue for this year and expects to make £62million. Shares surged 8.4 per cent, or 2.2p, to 28.5p.
From the daily mail this morning.
In a further dose of good news, Hvivo has already secured 90 per cent of its revenue for this year and expects to make £62million. Shares surged 8.4 per cent, or 2.2p, to 28.5p.
I would say that there is more of a chance of me being right, unless you are referring to the women’s super leaque
I have a feeling we may get more than 1 rns this week
HVIVO PLC will be holding a Company Presentation meeting on 30th Jan 2024 at 6:00pm GMT..
So update could be same day
It looks like there was just a purchase of £150,000. That’s a large buy
Over 600k shares traded in first 15 mins
I have had shares in this company previously.
In total I have purchase £29000 worth of shares in Hvivo this week. I believe this company has a very realistic chance of being bought out.
My buy of £22500 at 8.02 this morning is showing as a sell